Allogeneic Hematopoietic Progenitor Cell Therapy
Customize your policy alerts
Sign up for Centene Policy CP MP.249 alerts
Get alerted when Policy CP MP.249 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria for non‑Medicare Centene-affiliated health plans for allogeneic hematopoietic progenitor cell therapies including Omisirge (omidubicel) and RegeneCyte (HPC Cord Blood), and guidance for patient selection and coding.
RegeneCyte (HPC Cord Blood) criteria (Criteria II) were added to the policy.
Removed Omisirge-specific language from the policy title and broadened policy description to include multiple allogeneic HPC products.
Added note to refer to Medicare-specific policy MC.CP.MP.249 for Medicare criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.